Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 15/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454373 | 0.97 | KDM4E (0.47) | PPARALTA4HL3MBTL1PPARGKDM4E | |
| SCHEMBL5446064 | 0.90 | PPARA (0.58) | PPARALTA4HL3MBTL1PPARGKDM4E | |
| SCHEMBL5455623 | 0.89 | PPARA (0.44) | PPARALTA4HL3MBTL1PPARG | |
| SCHEMBL5450325 | 0.88 | ACACB (0.50) | PPARAL3MBTL1KDM4EMEN1ALDH1A1 | |
| SCHEMBL5447960 | 0.87 | HTR1A (0.46) | PPARAL3MBTL1PPARGMEN1KMT2A | |
| SCHEMBL5448535 | 0.86 | PPARA (0.56) | PPARALTA4HL3MBTL1PPARGKDM4E | |
| SCHEMBL5440996 | 0.85 | LTA4H (0.44) | PPARALTA4HL3MBTL1PPARG | |
| SCHEMBL5448541 | 0.85 | PPARA (0.56) | PPARALTA4HPPARG | |
| SCHEMBL5448510 | 0.83 | PPARA (0.47) | PPARAPPARGALDH1A1 | |
| SCHEMBL5455572 | 0.82 | PPARA (0.44) | PPARAL3MBTL1PPARGKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105847-A1 | 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | CADILA HEALTHCARE LIMITED (IN) | 2007-05-10 | — | — | US | claimed |
| EP-1709035-A1 | 1 , 3 - DIOXANE DERIVATIVES AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF I.A. OBESITY AND DIABETES | CADILA HEALTHCARE LTD. (IN) | 2006-10-11 | — | — | EP | claimed |
| WO-2005077943-A1 | 1 , 3 - DIOXANE DERIVATIVES AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF I.A. OBESITY AND DIABETES | CADILA HEALTHCARE LIMITED (IN) | 2005-08-25 | — | — | WO | claimed |
| US-20070105847-A1 | 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | CADILA HEALTHCARE LIMITED (IN) | 2007-05-10 | — | — | US | disclosed |
| EP-1709035-A1 | 1 , 3 - DIOXANE DERIVATIVES AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF I.A. OBESITY AND DIABETES | CADILA HEALTHCARE LTD. (IN) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005077943-A1 | 1 , 3 - DIOXANE DERIVATIVES AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF I.A. OBESITY AND DIABETES | CADILA HEALTHCARE LIMITED (IN) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105847-A1 | 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | GPR119, PPARG, FABP4 | PPARA 4/4885LTA4H 1854/4885L3MBTL1 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.